Therapeutic Asset Ratings
178 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
LEVODOPA
Opioid Dependence
Northwestern University
P2
CCC
(53)
LEVODOPA
Opioid Use
Northwestern University
P2
CCC
(53)
LEVODOPA
Pain;Back Low;Chronic
Northwestern University
P2
CCC
(53)
Lipitor
Ulcerative Colitis
Northwestern University
P2
CCC
(53)
Lisinopril
Metabolic Dysfunction-Associated Steatohepatitis
Northwestern University
P2
CCC
(53)
Metformin
Lung Carcinoma
Northwestern University
P2
CCC
(53)
Naproxen
Spinal Injury
Northwestern University
P2
CCC
(53)
Naproxen
Vertebral Column Disorder
Northwestern University
P2
CCC
(53)
Naproxen
Chronic Low-back Pain
Northwestern University
P2
CCC
(53)
Naproxen
Narcotic Use
Northwestern University
P2
CCC
(53)
Naproxen
Opiate Dependence
Northwestern University
P2
CCC
(53)
Naproxen
Substance-Related Disorder
Northwestern University
P2
CCC
(53)
Naproxen
Pain;Back Low;Chronic
Northwestern University
P2
CCC
(53)
PIFLUFOLASTAT
Prostate Carcinoma
Northwestern University
P2
CCC
(53)
PREDNISONE TABLETS
DNA Repair Disease
Northwestern University
P2
CCC
(53)
PREDNISONE TABLETS
Large B-Cell Lymphoma With IRF4 Rearrangement
Northwestern University
P2
CCC
(53)
Tranexamic Acid
BRCA Mutation
Northwestern University
P2
CCC
(53)
VINCRISTINE SULFATE
Large B-Cell Lymphoma With IRF4 Rearrangement
Northwestern University
P2
CCC
(53)
VINCRISTINE SULFATE
Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Northwestern University
P2
CCC
(53)
VINCRISTINE SULFATE
Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements
Northwestern University
P2
CCC
(53)
WP 1066
IDH-Wildtype Glioblastoma
Northwestern University
P2
CCC
(53)
Zanubrutinib
Diffuse Large B-Cell Lymphoma With Chronic Inflammation
Northwestern University
P2
CCC
(53)
Zanubrutinib
Epstein-Barr Virus-Positive Diffuse Large B-Cell Lymphoma Of The Elderly
Northwestern University
P2
CCC
(53)
Zanubrutinib
Intravascular Large B-Cell Lymphoma
Northwestern University
P2
CCC
(53)
Zanubrutinib
Large B-Cell Lymphoma With IRF4 Rearrangement
Northwestern University
P2
CCC
(53)
Showing 101 to 125 of 178 assets
Previous
Page 5 of 8
Next